TICKERNERD
Menu
ANGOANGOHealthcare · Medical Instruments & Supplies

ANGO Stock Forecast: AngioDynamics, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$11
+1.38% on the day

The 4 Wall Street analysts covering AngioDynamics, Inc. hold a median 12-month price target of $19 — +71.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 13 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$464.7M
Ticker Nerd rank
89 / 100
Median analyst target
$19
Analysts covering
4
Revenue$86.6M+8.0% y/y
Operating income−$5.5M
Net income−$11.4M
Free cash flow$17.0M
Quarterly, 8 quarters to 31 May 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−22.1%
1M
−28.8%
YTD
−13.9%
1Y
−3.2%
From 52W high
−31.5%
From 52W low
+13.9%
$10
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANGO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AngioDynamics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Oct 2026
89 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
92
Quality
85
Momentum
76
Volatility
73
Value
68
Revisions
66
Size
54
Growth
52
Issuance
41

Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (41): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ANGO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANGO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25Jan 26Apr 26Jul 26Oct 26ANGOHigh $24Median $19Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $17Median $19High $24

The green dot is the last close — the median target sits +71.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
13 Oct 2026HC Wainwright & Co.MaintainsBuy$19 → $18
9 Oct 2026Canaccord GenuityMaintainsBuy$20
15 July 2026Canaccord GenuityMaintainsBuy—
15 July 2026Canaccord GenuityMaintainsBuy$16 → $20
15 July 2026HC Wainwright & Co.MaintainsBuy—
15 July 2026HC Wainwright & Co.MaintainsBuy$16 → $19
6 Apr 2026Canaccord GenuityMaintainsBuy$18 → $16
6 Apr 2026Canaccord GenuityMaintainsBuy—
6 Apr 2026Freedom BrokerInitiatesBuy$16
6 Apr 2026Freedom BrokerInitiatesBuy—
3 Oct 2025Canaccord GenuityMaintainsBuy—
16 July 2025Canaccord GenuityMaintainsBuy—
16 July 2025HC Wainwright & Co.ReiteratesBuy—
16 July 2025Lake StreetInitiatesBuy—
7 Apr 2025HC Wainwright & Co.MaintainsBuy—
10 Jan 2025HC Wainwright & Co.MaintainsBuy—
9 Jan 2025Canaccord GenuityMaintainsBuy—
10 Dec 2024HC Wainwright & Co.ReiteratesBuy—
4 Oct 2024Canaccord GenuityMaintainsBuy—
4 Oct 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANGO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ANGO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, AngioDynamics, Inc. returned −3.2% against +17.5% for the S&P 500, dividends included.

ANGO vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140Jan 26Apr 26Jul 26Oct 26ANGOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ANGO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

AngioDynamics, Inc. (ANGO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
41.4×

Cheaper than 18% of US stocks

Price / sales
1.4×

Cheaper than 59% of US stocks

Price / book
2.9×

Cheaper than 31% of US stocks

EV / EBITDA
331.4×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
6.9%

Higher than 44% of US stocks

Earnings growth (YoY)
8.0%

Higher than 45% of US stocks

Gross margin
54.0%

Higher than 66% of US stocks

Operating margin
−7.8%

Higher than 25% of US stocks

Net margin
−10.1%

Higher than 20% of US stocks

Returns & dividend
Return on equity
−19.2%

Higher than 32% of US stocks

Return on assets
−5.1%

Higher than 32% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

AngioDynamics, Inc. (ANGO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AngioDynamics, Inc. has a market value of $464.7M and an enterprise value of $435.2M.

  • Revenue in the twelve months to 31 May 2026: $320.2M. The latest quarter grew 6.9% year on year.

  • Net income over the same four quarters: −$36.7M, a −11.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.87.

  • Free cash flow in the twelve months to 31 May 2026: $508K, after $2.6M of capital spending.

  • AngioDynamics, Inc. spent $0.0 on share buybacks in the twelve months to 31 May 2026.

  • Shares outstanding: 41.7M.

  • Trailing P/E: 41.4×; forward P/E: −116.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • AngioDynamics, Inc. employs 632 people — $507K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 May 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

ANGO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
ANGOAngioDynamics, Inc.$464.7M
89
EMBCEmbecta Corp.$367.2M
83
NNNNAnbio Biotechnology$613.0M
17
ZJYLJin Medical International Ltd.$325.9M
13
SMTISanara MedTech, Inc.$322.9M
91
OSUROraSure Technologies, Inc.$263.4M
87
UTMDUtah Medical Products, Inc.$237.9M
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AngioDynamics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANGO news & analysis

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

Business Wire · 14 Oct 2026positive

AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to apply LCD L40205 medical necessity criteria for irreversible electroporation (IRE). The headline says the policy supports broader access to NanoKnife IRE for prostate and liver cancer.

Why it matters — The coverage-policy update is relevant to ANGO watchers because it concerns patient access to the company’s NanoKnife IRE technology.

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

Zacks Investment Research · 9 Oct 2026positive

AngioDynamics beat first-quarter earnings estimates, with revenue up 6.9% year over year on strong Med Tech growth. The excerpt also cites margin expansion and robust Auryon and NanoKnife sales.

Why it matters — The earnings beat and growth in Med Tech and product sales are key details for ANGO watchers assessing the quarter.

AngioDynamics Stock Is Falling Thursday: What's Going On?

Benzinga · 8 Oct 2026negative

AngioDynamics shares fell more than 21% on Thursday despite the company reporting better-than-expected first-quarter financial results.

Why it matters — ANGO watchers may note the sharp stock decline occurred even though quarterly results exceeded expectations.

AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript

Seeking Alpha · 8 Oct 2026neutral

Seeking Alpha published a transcript of AngioDynamics, Inc.’s Q1 2027 earnings call.

Why it matters — The transcript provides ANGO watchers with the company’s discussion during its Q1 2027 earnings call.

Why AngioDynamics Crashed Today

The Motley Fool · 8 Oct 2026negative

AngioDynamics reported results that beat expectations on both revenue and earnings, though it still posted a pro forma loss of $0.04 per share. Its GAAP loss was four times larger.

Why it matters — ANGO watchers may note that the reported beats came alongside continued losses, with the GAAP loss substantially exceeding the pro forma loss.

FAQ

Frequently asked questions about ANGO stock

What is the ANGO stock price forecast for 2026-2027?

The 4 Wall Street analysts covering AngioDynamics, Inc. have a median 12-month price target of $19, with estimates ranging from $17 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANGO stock a buy right now?

Of the 4 analysts covering AngioDynamics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AngioDynamics, Inc. 89 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANGO?

As at 13 Oct 2026, AngioDynamics, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).

Will ANGO stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +71.9% from the last close, and Ticker Nerd's factor model ranks AngioDynamics, Inc. 89 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANGO stock forecast for 2030?

No analyst covering AngioDynamics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $24 over the next 12 months.

How has ANGO stock performed over the past year?

AngioDynamics, Inc. returned -3.2% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AngioDynamics, Inc. do?

AngioDynamics Inc. is a medical technology company that develops, manufactures, and markets minimally invasive medical devices for healthcare providers.

What is the latest news on ANGO?

The most recent item we track (Business Wire, 14 Oct 2026): "AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer". AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to apply LCD L40205 medical necessity criteria for irreversible electroporation (IRE). The headline says the policy supports broader access to NanoKnife IRE for prostate and liver cancer.

Company

About AngioDynamics, Inc.

AngioDynamics Inc. is a medical technology company that develops, manufactures, and markets minimally invasive medical devices for healthcare providers. Its product portfolio supports image-guided procedures across vascular intervention, vascular access, oncology, and surgical care, with devices used to treat peripheral vascular disease and other non-coronary conditions. The company offers a broad range of therapeutic and diagnostic products, including atherectomy systems, venous therapies, ablation technologies, fluid management tools, dialysis access products, drainage devices, and angiographic accessories. AngioDynamics serves hospitals, health systems, ambulatory procedure sites, and specialist physicians, primarily in the United States, with additional international sales through distributors and direct channels. Headquartered in Latham, New York, AngioDynamics plays a specialized role in the medical device market by providing tools designed for minimally invasive treatment and procedural precision.

CEO Mr. James C. Clemmer · 632 employees · United States · https://www.angiodynamics.com